First Patient Dosed in EVICTION Trial Evaluating ImCheck’s Lead Anti-Cancer Drug, ICT01: A Novel Gamma Delta T Cell-Activating Immunotherapy

​

​

ImCheck Achieves Initial Positive Independent Safety Review and Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01

​

​

Preliminary Results in Solid Tumor Patients with ICT01, a First-in-Class, γ9δ2 T Cell Activating Antibody Targeting Butyrophilin 3A

​

Preliminary Results in Solid Tumor Patients with ICT01, a First-in-Class, γ9δ2 T Cell Activating Antibody Targeting Butyrophilin 3A

​

​

Smart Immune Receives IRB Approval For Phase 1/2 Clinical Trial of Proprietary Allogeneic T-cell Product Smart-101 (ProTcellTM) for AML and ALL
Trial to commence in November 2021

​

ImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC Annual Meeting 2022​​​​​​

​

​

Enhancing the Anti-tumor Immunity and Therapeutic Potential of ICT01 a Butyrophilin 3A γ9δ2 T Cell-Activating Monoclonal Antibody with Low Dose IL-2 in Patients with Advanced Solid Tumors

First-in-Human Study of ICT01, an Anti-BTN3A Activating Monoclonal Antibody in Combination with Low Dose IL-2 in Patients with Advanced Solid Tumors

​